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SUMMARY 
Rabbits were immunized with the sera from patients with known Au antigenaemia; 
from kidney homograft recipients who were Au negative with direct conventional 
tests but who had hepatic dysfunction; and from normal volunteers. Heterologous 
anti-Au antibodies were raised by the first of these kinds of sera but not by the 
third. Sera from seven ofthe eleven immunosuppressed kidney recipients of the second 
group did not raise anti-Au antibodies in the rabbit, but sera from the other four did. 
The results indicate that the Au antigen may be present in trace quantities in signi-
ficant numbers of immunosuppressed patients previously thought to be Au negative. 
However, they do not unequivocally establish an aetiologic association between Au 
antigenaemia and 'post-transplantation liver disease', probably because of the ob-
scuring and important factor of hepatotoxicity of the immunosuppressive agents. 
INTRODUCTION 
Post-transplantation liver disease is a well-recognized complication of renal homotrans-
plantation under immunosuppression. A clear association between this kind of liver disease 
and the presence or absence of the Australia (Au) antigen could not be established in a 
recent study from our institution (Torisu et al., 1971). Particularly troubling was a group of 
eleven recipients who had severe or even fatal hepatic damage but who never had the Au 
antigen in any of multiple stored postoperative serum samples. The present study using a 
heterologous antiserum system was designed to see if some of these eleven patients did, in 
fact, have the Au antigen which was missed because of the insensitivity of the detection 
methods. 
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METHODS 
Detection of Au antigen 
The Au antigen and anti-Au antibody were looked for in all subjects entered into this 
study with Ouchterlony's (1958) micro-method (AG), immuno-electro-osmophoresis 
(lEOP) (Bussard, 1959; Prince & Burke, 1970), complement fixation (CF) (Sever, 1962; 
Shulman & Barker, 1969) and haemagglutination (HA) or haemagglutination inhibition 
(HAT) (Vyas & Shulman, 1970) tests. In addition, anticomplementary activity (ACA), 
which is thought to measure circulating Au antigen anti-Au antibody complexes, was deter-
mined (Mayer, 1961; Shulman & Barker, 1969; Torisu et al., 1971). 
Case material 
Au antigen and anti-Au antibody standard sources. Two renal transplant recipients under 
immunosuppression with chronic Au antigenaemia provided sera with high titre reference 
antigen. Human anti-Au antiserum was donated by a third kidney recipient who had 
developed chronic aggressive hepatitis in the post-transplantation period without ever 
having demonstrable Au antigen. 
Control patients with Au antigenaemia. Multiple serum samples were collected from five 
additional patients with the Au antigen. Three of these patients were under immuno-
suppression after renal homotransplantation, but did not have severe hepatitis. The other 
two, who had never received immunosuppressive therapy, had typical acute serum hepatitis. 
Patients without Au antigenaemia. Sera from eleven kidney recipients with post-trans-
plantation hepatic dysfunction were collected starting about 1 week before the onset of 
liver dysfunction and continuing until I week after recovery or, in three instances, until 
death. These cases, which have been previously reported (Torisu et al., 1971), are listed in 
Table 1. 
Negative controls. The sera from 200 healthy volunteers were pooled. These individuals 
were all Au-negative by the complement fixation test. 
Preparation of rabbit antiserum 
Against Au antigen standard. Two 3 kg rabbits were immunized with a standard Au antigen 
(Fig. 1) after first complexing the antigen in pooled stored sera by the following method. 
2 ml of Au positive serum were added to an equivalent dose of human anti-Au IgG fraction 
in the presence of 0·02 M EDTA. The mixture was kept at 37°C for 4 hr and then 4°C for 
48 hr. The precipitate of antigen-antibody complexes was collected by centrifugation at 
6000 rpm for 30 min, washed three times in 0·02 M EDT A and twice in saline, and resuspen-
ded in saline to contain I mg/ml protein as determined by the method of Folin & Ciocalteu 
(1927).2 ml of this immune complex was suspended in 2 ml of complete Freund's adjuvant 
and injected in multiple intramuscular sites. After 2 weeks, 2 ml of the complex with an 
equal volume of Freund's adjuvant were injected into multiple subcutaneous sites. One week 
later, the rabbits were given the first of three weekly immunizations of 1 ml of complex, first 
by the intramuscular, then subcutaneous, and finally intraperitoneal routes. The animals 
were bled 2 weeks after the last injection. 
To 40 ml of the rabbit antiserum was added partially purified human IgG in order to 
remove antigammaglobulin antibodies. The mixture was kept at 37°C for 4 hr and 4°C for 
48 hr. After centrifugation at 6000 rev/min for 30 min, the supernatant was collected and its 
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JgG fraction obtained by ammonium sulphate fractionation followed by DEAE-cellulose 
chromatography. 
Control patients with Au antigenaemia. All the serum samples for each individual patient 
were pooled before reseparation into immunizing aliquots. Two rabbits weighing 3·0-3·5 kg, 
whose sera did not contain antihuman protein antibody, were immunized against the pooled 
sera of each of the five control patients (Fig. 1). The injections of 2 ml with an equal volume 
of Freund's adjuvant were made into the foot pads. After 2 weeks, the same material was 
injected into multiple subcutaneous sites. After another 2 weeks, weekly immunization with 
I ml of pooled serum was by three different routes alternating from intramuscular to intra-
peritoneal to subcutaneous sites. Only one cycle of this rotating schedule was actually 
carried out before immunization was discontinued, since the rabbits readily developed anti-
Au antibody (Table 2). 
TABLE 1. 'Australia antigen negative' patients with liver dysfunction 
Liver dysfunction Heterologous 
anti-Au antibodies 
Patient Sex Age Duration Grade raised with sera 
LD-176 F 13 2 weeks + No 
LD-199 M 38 3 weeks ++ Yes 
LD-209 M 38 9 weeks + No 
LD-246 F 41 13 weeks ++ No 
LD-262 F 11 4 months +++ No 
LD-263 F 28 3 months +++ Yes 
LD-264 F 41 3 weeks + No 
LD-268 M 24 6 weeks ++ No 
CD-17 F 17 32 months +++ Yes 
CD-34 F 19 14 months + Yes 
CD-52 F 13 3 months + No 
Liver dysfunction grade: + + +, liver disease caused or contributed to 
death; + +, severe liver dysfunction; +, minor changes in liver function. 
The sera collected from each pair of rabbits immunized against the sera of one of the five 
humans were absorbed with pooled serum from 100 normal human volunteers who were 
Au negative by the complement fixation technique. This step was designed to remove 
extraneous anti-human protein antibodies. 
Patients without Au antigenaemia. Immunization of two rabbits was carried out with the 
pooled sera of each of the eleven patients (Fig. 1). The rotating injection schedule described 
in the previous section was continued for as long as 7 months or for whatever portion of 
that interval was required to develop heterologous anti-Au antibody. 
The same absorption schedule as in the preceding section was carried out. 
Negative controls. Aliquots of the pooled sera were used to immunize five rabbits for 
6 months by the schedule described above, and the rabbit antisera were absorbed by the 
same methods. 
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RESULTS 
Anti-Au activity of rabbit antisera 
Raised against Au antigen standard. The rabbit IgG purified from antisera raised against 
immune complexes was tested on an Ouchterlony plate against the standard Au antigen 
sera and against the five Au positive controls. A single but broad precipitin line was formed 
(Fig. 1, plates A and B). 
Raised against patients with Au antigenaemia. All five of the absorbed rabbit antisera 
raised against the sera of the Au positive control patients contained anti-Au activity when 
tested against any of these five control sera in the central Ouchterlony well (Fig. 1, plate B) 
or against the Au antigen standard sera (Fig. I, plate A). 
Raised against patients without Au antigenaemia. Seven of the eleven rabbit pairs im-
munized against Au negative pooled human sera failed to develop anti-Au antibodies 
despite immunization for as long as 7 months. However, anti-Au antibody was detected in 
the four other rabbit pairs 12, 15,23 and 24 weeks after commencing immunization (Table 
2). This activity was detected against the Au antigen standards (Fig. 1, plate A) as well as 
against all five of the control Au positive human sera (Fig. I, plate B), and in each instance 
was manifested as a broad single precipitin line. However, the antisera raised by the four 
Australia negative sera did not react in any perceptible way with these four sera (Fig. 1, 
plate C) or with the seven others. 
Negative controls. The rabbit antisera raised against pooled normal human serum did 
not possess any anti-Au activity (Fig. I). 
The identification of the antibodies 
The broad single precipitin lines in the rabbit antisera raised against the Au negative 
human sera were identical to the precipitin lines produced by rabbit immunization with Au 
positive sera (Fig. 2), and fused with the much finer precipitin line formed by human anti-Au 
serum. 
Clinical correlations 
The eleven transplant patients with negative Au antigen by conventional techniques had 
the spectrum of liver disease shown in Table 1. The severity of hepatic dysfunction in the 
four patients whose sera raised anti-Au antibody in the rabbit was somewhat more severe 
than in the other seven patients, but both subgroups had variations from mild to fatal. 
DISCUSSION 
The primary subjects of this investigation were eleven patients with hepatic dysfunction 
following transplantation of the kidney in whom no evidence could be found of the hepatitis 
associated or Australia (Au) antigen by multiple tests including the highly sensitive comple-
ment fixation (Sever, 1962; Shulman & Barker, 1969) and HA or HAl (Vyas & Shulman, 
1970) examinations. To unmask any examples of false Au negative, a 'biologic assay' was 
performed in which it was assumed that Au antigen was present in the sera of these patients 
and in sufficient quantities to hyperimmunize rabbits. The heterologous antisera raised 
against the sera of seven of the eleven patients did not support the foregoing premise in that 
no heterologous anti-Au antibodies ever became detectable. 
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FIG. 1. Schematic representation of the methods and results. The upper portion of the figure 
diagrams the preparation of three kinds of rabbit antisera, each of which was then placed in a 
peripheral well of the agar plate, as indicated by the thin arrows. The fifth and sixth wells were 
filled with rabbit antisera to normal human serum and human anti-Au antiserum, respectively. 
The central well of plate A was charged with standard Au positive serum (broad arrow). The 
peripheral wells of the other two plates contain the same antisera in identical locations as 
plate A. However, the central wells were filled with control Au positive serum (plate B) or the 
serum from an 'Au negative' patient who by biologic assay had detectable Au antigen (plate C). 
Note the broad precipitin line in plates A and B and the absence of visible reaction in C. 
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FIG. 2. Ouchterlony diffusion plate showing precipitin reactions of various antisera with the 
standard Au antigen (central well). Rabbit antisera raised against sera of patients CD-17, 
CD-34, LD-263 and LD-199, all thought to be 'Au negative,' were placed in peripheral wells 
I, 3,4 and 6, respectively. Well 2 was filled with human anti-Au antisera and well 5 with rabbit 
antiserum raised against standard Au antigen. All lines were identical, although the rabbit 
antisera produced broader precipitin bands than the human antiserum. 
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However, the pooled sera from each of the other four test patients did raise anti-Au 
antibodies in the rabbit which by agar gel diffusion were indistinguishable from those 
produced by immunizing with known Au positive human serum. These four patients, of 
whom two died primarily of liver complications, may have been suffering from serum 
hepatitis but with quantities of circulating Au antigen so minute that detection was not 
possible by any direct technique of examination. The indirect method of detection by 
rabbit immunization employing Freund's adjuvant and then testing against high titre Au 
standard serum was evidently not dependent on so high a level of antigen in the patient's 
sera. For epidemiologic purposes these four patients probably should be considered 
infectious carriers in the same sense as has been defined in other transplantation patients 
whose chronic Au antigenaemia could be identified with more conventional methods 
(Torisu et al., 1971). 
The evidence for Au antigen in these additional four patients with post-transplantation 
liver disease does not establish a cause-and-effect relationship for the hepatic malfunction as 
was stressed in a recent publication (Torisu et al., 1971). Many immunosuppressed patients 
with chronic Au antigenaemia have no hepatic dysfunction whereas others, such as the 
majority of those in the present report, may have significant liver disease without any 
serologic findings whatever of serum hepatitis. In the latter patients or even in many Au 
--~--K---K----------
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positive patients with hepatic malfunction, the principal cause of the liver findings could be 
hepatotoxicity of the immunosuppressive agents, particularly azathioprine. Support for 
this possibility has been provided by the prompt improvement in patients in whom azathio-
prine therapy was stopped because of abnormalities in liver function and replaced with 
cyclophosphamide (Torisu et at., 1971; Starzl et al., 1971). 
The kind of study herein reported may be useful in investigating poorly understood 
hepatic diseases apart from those seen with immunosuppression and transplantation. An 
example is chronic aggressive hepatitis, a disorder that is associated with serum hepatitis 
and Au antigenaemia in about a quarter of the cases (Bulkley et al., 1970; Vischer, 1970). 
It is probable that some or even many of the other three-quarters, said to be Au negative, 
also could be shown to be Au positive with the heterologous antiserum system. 
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